The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
Subjects will undergo a placebo and allopurinol phase to better understand the effects of the
reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Open Medicine Institute